Enovis Corp (ENOV) Stock Forecast & Price Target

Enovis is expected to achieve its HSD/LDD growth range, expand gross margins by approximately 210bps through a mix of new product uptake and divestiture of Dr. Comfort, and improve its competitive position through the reclassification of non-invasive bone growth stimulators from Class III to Class II by the FDA. By 2026, Enovis is expected to earn around $425M-$435M in adj. EBITDA and $3.52-$3.73 in adj. EPS with favorable margin and revenue mix outlook.

Enovis is a company primarily focused on orthopedics that has seen steady growth in recent years through its multi-segment approach. Despite launching new products and outperforming underlying markets, the company is expected to face headwinds due to softer volumes and conflicts in certain regions. With a relatively low valuation compared to its peers, the market may have written off Enovis as a smaller player with lower cash flow potential and higher tariff exposure. While the company is likely to face some impact from reduced reimbursements in certain product categories, its exposure to these areas is limited and manageable. Overall, the stock may offer an attractive entry point for investors looking for steady performance and potential opportunities in targeted submarkets.